A new clinical trial at the Medical College of Wisconsin (MCW) offers a glimmer of hope in the fight against preeclampsia, a potentially life-threatening high blood pressure condition that affects up to 8 percent of pregnant women globally. Researchers are investigating whether the antioxidant supplement MitoQ can improve vascular function and ultimately lead to healthier pregnancies for both mothers and babies. The study, funded by a $900,000 grant from the Gates Foundation through Grand Challenges, represents a significant step toward understanding and treating a condition that currently has limited therapeutic options.
Preeclampsia remains a major concern in maternal health, often requiring early delivery to protect the mother, which can lead to complications for the newborn. The condition’s underlying causes are still not fully understood, making effective prevention and treatment challenging. Currently, the only definitive treatment for severe preeclampsia is delivery of the baby, which can result in premature birth and intensive care for the infant. This new research focuses on improving vascular function, a key area believed to be impacted by the condition, offering a potential pathway to prolonging pregnancies and improving outcomes.
The clinical trial, led by Jennifer McIntosh, MS, DO, associate professor of obstetrics and gynecology and a maternal fetal medicine specialist at MCW, will enroll 70 patients diagnosed with preeclampsia. Participants will be randomly assigned to receive either MitoQ or a placebo over the next two years. “There is currently no medication that can cure preeclampsia or really even hold it at bay,” Dr. McIntosh explained. The research team, which includes Matt Durand, PhD, associate professor of anesthesiology, and Bill Hughes, PhD, assistant professor of anesthesiology, hopes to identify a safe and effective way to manage the condition and reduce its devastating consequences.
Unraveling the Role of Mitochondria in Preeclampsia
Dr. McIntosh’s research centers on the possibility that preeclampsia involves damage to mitochondria, the powerhouses of cells. Her team’s previous operate demonstrated that mitochondrial antioxidants improved vascular function in animal models and in human placentas from patients with preeclampsia, suggesting a potential therapeutic target. This builds on growing research exploring the role of mitochondrial dysfunction in a range of health conditions, including cardiac disease and diabetes.
MitoQ, the supplement being tested in the trial, is designed to protect mitochondria from oxidative damage. Studies have shown it to be well-tolerated and to improve vascular function in other populations, such as older adults, with improvements of up to 50 percent reported in some studies, according to Dr. Hughes. “Now Dr. McIntosh is taking it a step further and looking at it for this pregnant population that currently has no available treatment,” he said.
A Low-Cost Solution with Global Potential
The trial will meticulously assess vascular function in participants, using ultrasound to measure the diameter and dilation of the brachial artery, a major blood vessel in the upper arm, as well as laser measurements to assess small vessel function. Blood draws will be used to measure oxidative stress levels, and placental health will be evaluated after delivery. This comprehensive approach aims to provide a detailed understanding of MitoQ’s impact on vascular health in preeclampsia.
The researchers emphasize the potential for MitoQ to be a particularly impactful treatment due to its low cost and stability. If the trial results are promising, the team plans to pursue a larger, multi-center clinical trial that could include hospitals in developing countries, where preeclampsia poses a particularly severe threat. “Preeclampsia is devastating in the United States, but it’s extremely devastating in underdeveloped countries,” Dr. McIntosh stated. “I’ve practiced in obstetric units in Kenya and Malawi, and most days of the week, someone died from preeclampsia, either a mom or a baby, because of the lack of resources that we take for granted here. The idea that we could have a treatment that is simple, shelf-stable, and inexpensive to help prevent deaths worldwide is pretty exciting.”
The MCW team’s proposal stood out among 1,000 applicants and five rounds of review for the Grand Challenges grant, with the Gates Foundation ultimately increasing the funding to support an expanded research scope. This underscores the significance of the project and the potential for MitoQ to address a critical global health challenge. The Grand Challenges initiative, supported by the Gates Foundation, aims to foster innovation and collaboration in tackling pressing global health issues.
This early-stage study will primarily focus on evaluating the safety and biological markers of vascular function. Successful results could pave the way for larger-scale trials and, a new treatment option for preeclampsia, offering hope to millions of pregnant women worldwide. The team is hopeful that this research will translate into improved outcomes and reduced suffering for both mothers and their babies.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The research team will continue to enroll patients and analyze data over the next two years. Updates on the trial’s progress and findings will be available through the National Institutes of Health’s ClinicalTrials.gov website. Share this article to help raise awareness of this key research and its potential to improve maternal health globally.
